Swedish private‑equity house EQT has exited its investment in Viking Line, the Finnish‑Swedish ferry operator that services routes across the Baltic Sea. The firm sold its minority stake to an undisclosed buyer, completing a divestiture that began after the 2022 acquisition of a larger share. The move frees capital for EQT to pursue new infrastructure deals in Europe. The deal signals EQT’s shift to renewables.

US buyout specialist GTCR closed on its purchase of Zentiva, a Czech‑based generic drug maker that produces branded specialty and over‑the‑counter medicines. The transaction values the business at roughly €1.2 billion, adding a steady‑cash pharmaceutical platform to GTCR’s health‑care portfolio. Zentiva’s broad product lineup and pan‑European manufacturing footprint should bolster the fund’s earnings visibility. The acquisition also expands GTCR’s presence in Eastern Europe.

Both exits illustrate how private‑equity firms are reshuffling assets to align with sector trends. EQT’s retreat from transport frees liquidity for higher‑margin infrastructure bets, while GTCR’s entry into generics taps growing demand for cost‑effective medicines amid tightening healthcare budgets. Investors will watch how these reallocations affect fund performance and portfolio risk profiles this year.